Syndax Pharmaceuticals Inc (SNDX)
A
Pipeline Grade
Financial Position (from SEC Filings)
$28.2M
Cash & Equivalents
$50.3M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$1,738M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
REVUMENIB CITRATE
REVUFORJ |
APPROVED | Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemias, Acute Undifferentiated Leukemia, AML, AML With Gene Mutations, AML, Adult, ARDS, Bladder Cancer, Blinatumomab, Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Chronic Graft-versus-host-disease, Colorectal Cancer, Coronavirus, COVID, Cytokine Release Syndrome, Cytokine Storm, Digestive System Neoplasms, Drug Interaction, Endocrine Gland Neoplasms, Epigenetic Therapy, Epithelial Ovarian Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer, ER+ Breast Cancer, Estrogen Receptor Breast Cancer, Estrogen Receptor Positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Healthy Volunteer, He |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine ... | PHASE2 | Recruiting | 43 |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | PHASE2 | Active Not Recruiting | 46 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.